Video assisted thoracic surgery vs. thoracotomy for locally advanced lung squamous cell carcinoma after neoadjuvant chemotherapy

被引:26
|
作者
Fang, Likui [1 ]
Wang, Luming [1 ]
Wang, Yiqing [1 ]
Lv, Wang [1 ]
Hu, Jian [1 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Dept Thorac Surg, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
基金
国家重点研发计划;
关键词
Locally advanced lung squamous cell carcinoma; Neoadjuvant chemotherapy; Video assisted thoracic surgery; Thoracotomy; INDUCTION CHEMORADIOTHERAPY; THORACOSCOPIC LOBECTOMY; CANCER; THERAPY; N0; CHEMORADIATION; COMPLICATIONS; RADIOTHERAPY; METAANALYSIS; RESECTION;
D O I
10.1186/s13019-018-0813-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundSurgery is an important part of multidisciplinary treatment strategy for locally advanced lung squamous cell carcinoma (LSCC), but insufficient evidence supports the feasibility and safety of video assisted thoracic surgery (VATS) following neoadjuvant chemotherapy for locally advanced LSCC. This study aims to compare perioperative data and long-term survival of locally advanced LSCC patients between VATS and thoracotomy after neoadjuvant chemotherapy.MethodsWe retrospectively collected the clinical and pathological information of patients with locally advanced LSCC who underwent surgical resection after neoadjuvant chemotherapy from October 2013 to October 2017. All patients were divided into two groups (thoracotomy and VATS) and were compared the differences in perioperative, oncological and survival outcomes.ResultsA total of 81 patients were analyzed in this study (67 thoracotomy and 14 VATS). VATS provided less postoperative pain (P=0.005) and produced less volume of chest drainage (P=0.019) than thoracotomy, but the number of resected lymph nodes was less in VATS group (P=0.011). However, there was no significant difference in the number of resected lymph node stations and the rate of nodal upstaging between two groups. The mean disease free survival (DFS) was 32.72.7months for the thoracotomy group and 31.8 +/- 3.0months for the VATS group (P=0.335); the corresponding overall survival (OS) was 41.7 +/- 2.2months and 36.4 +/- 4.1months (P=0.925).Conclusion In selected patients with locally advanced LSCC, VATS played a positive role in postoperative recovery and associated similar survival outcome compared with thoracotomy after neoadjuvant chemotherapy.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Video assisted thoracic surgery vs. thoracotomy for locally advanced lung squamous cell carcinoma after neoadjuvant chemotherapy
    Likui Fang
    Luming Wang
    Yiqing Wang
    Wang Lv
    Jian Hu
    Journal of Cardiothoracic Surgery, 13
  • [2] Video-assisted Thoracic Surgery Versus Thoracotomy for Nonsmall-cell Lung Cancer
    Pan, Tie-Wen
    Wu, Bin
    Xu, Zhi-Fei
    Zhao, Xue-Wei
    Zhong, Lei
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (02) : 447 - 450
  • [3] Neoadjuvant chemoradiotherapy versus chemotherapy and surgery for patients with locally advanced esophageal squamous cell carcinoma
    Hao, Daxuan
    Li, Xue
    Yang, Yuanyuan
    Zhang, Yougai
    Wu, Xiaoyuan
    Chen, Yongshun
    Wang, Jianhua
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 (02) : 346 - 353
  • [4] Uniportal video-assisted thoracoscopic surgery following neoadjuvant chemotherapy for locally-advanced lung cancer
    Yang, Zhiqiang
    Zhai, Chunbo
    JOURNAL OF CARDIOTHORACIC SURGERY, 2018, 13
  • [5] Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma
    Lu, Hao
    Liu, Jun-Feng
    Rong, Yu
    Liu, Xin-Bo
    Wang, Yan
    JOURNAL OF GASTROINTESTINAL SURGERY, 2024, 28 (06) : 867 - 869
  • [6] Neoadjuvant therapy of locally advanced squamous cell carcinoma of the esophagus Radiochemotherapy vs. doublet or triplet chemotherapy alone
    Drabke, Sophia
    Kaufmann, Justus
    Schmidberger, Heinz
    STRAHLENTHERAPIE UND ONKOLOGIE, 2024, 200 (12) : 1100 - 1102
  • [7] Video-Assisted Thoracic Surgery vs. Thoracotomy for the Treatment in Patients With Esophageal Leiomyoma: A Systematic Review and Meta-Analysis
    Shen, Cheng
    Li, Jue
    Che, Guowei
    FRONTIERS IN SURGERY, 2022, 8
  • [8] Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients
    Chen, Chih-Yi
    Li, Chia-Chin
    Chien, Chun-Ru
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
  • [9] Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma
    Lv, Huilai
    Zhang, Fan
    Huang, Chao
    Xu, Shi
    Li, Jiachen
    Sun, Bokang
    Gai, Chunyue
    Liu, Zhao
    Wang, Mingbo
    Li, Zhenhua
    Tian, Ziqiang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (05)
  • [10] Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Zhao, Jidong
    He, Ming
    Li, Jie
    Li, Dan
    Zhao, Yang
    Li, Xinhui
    Zhang, Xiangmei
    Chen, Xin
    Liu, Yunjiang
    Zhao, Liyan
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2022, 37 (04) : 324 - 331